Infection | Pathogens | Number | Treatment | Mortality | Reference |
---|---|---|---|---|---|
Bacteremia | KPC | 125 | Monotherapy | 25/46 (54%) | [23] |
K. pneumoniae | Combination therapy | 27/79 (34%) | |||
7/23 (30%) | |||||
Colistina + tigecyclineb | 6/12 (50%) | ||||
2/16 (12%) | |||||
Tigecycline + gentamicinc | |||||
Colistin + tigecycline + meropenemd | |||||
Bacteremia | KPC | 41 | Monotherapy | 11/19 (58%) | [22] |
K. pneumoniae | Combination therapye | 2/15 (13%) | |||
1/5 (20%) | |||||
Colistin + carbapenem | 0/3 (0%) | ||||
0/2 (0%) | |||||
Tigecycline + carbapenem | |||||
Tigecycline + aminoglycoside | |||||
Trauma ICU | KPC | 26 | Combination therapy | 2/26 (8%) | [33] |
VAP | K. pneumoniae | ||||
Bacteremia | Tigecyclinef + gentamicing ± fosfomycinh | ||||
Tigecycline plus colistini ± fosfomycin | |||||
Bacteremia | Acinetobacter | 28 | Monotherapy (colistinj) | 2/5 (40%) | [17] |
VAP | Pseudomonas | Combination therapy | 3/14 (21Â %) | ||
KPC K. pneumoniae | Colistin + aminoglycoside | ||||
Colistin plus carbapenem | |||||
ICU | KPC K. pneumoniae | 11 | Combination therapy | 2/11 (18%) | [34] |
VAP ± bacteremia | |||||
UTI, wound | Fosfomycink + colistin | ||||
Fosfomycin + gentamicin | |||||
Fosfomycin + piperacillin/tazobactam | |||||
ICU bacteremia | KPC K. pneumoniae | 48 | Combination therapy | 18/48 (37.5%) | [35] |
VAP | Pseudomonas | Fosfomycinl + colistin | |||
Fosfomycin + tigecycline | |||||
UTI | KPC K. pneumoniae | 21 | Gentamicin | 0/7 (0%) | [36] |
Other | 0/7 (0%) | ||||
Doxycycline | |||||
Ciprofloxacin | |||||
Nitrofurantoin | |||||
Colistin | |||||
UTI (including colonization) | CRE | 136 | Treatment receivedm | 9/136 (7%) | [37] |
Polymyxin B | |||||
Tigecycline | |||||
Aminoglycoside | |||||
 |  |  | No treatment |  |  |